羥氯喹聯合潑尼松治療風濕免疫系統疾病的臨床療效對照研究

蔣雪玲

[摘要] 目的 探析羥氯喹聯合潑尼松治療風濕免疫系統疾病的臨床療效。方法 方便選取2017年5月—2019年5月在該院接受治療的109例風濕免疫系統疾病患者予以分組研究，隨機分為對照組（n=54）與研究組（n=55）。對照組患者給予潑尼松治療，研究組患者給予羥氯喹聯合潑尼松治療，比較兩組患者臨床療效、不良反應發生率、關節腫脹指數及疼痛指數。結果 對照組患者臨床總有效率為81.48%，研究組患者為94.55%，研究組顯著高于對照組（χ2=4.427，P<0.05）。對照組患者不良反應發生率為7.41%，研究組患者為9.09%，數據比較差異無統計學意義（χ2=0.102，P>0.05）。治療前，對照組患者關節腫脹指數、疼痛指數分別為（3.82±0.95）分、（3.50±0.84）分，研究組患者分別為（3.81±0.93）分、（3.52±0.81）分，數據比較差異無統計學意義（t=0.120、0.220，P>0.05）;治療后，對照組患者關節腫脹指數、疼痛指數分別為（1.77±0.51）分、（1.71±0.37）分，研究組患者分別為（0.68±0.42）分、（0.66±0.31）分，研究組顯著低于對照組（t=6.540、6.820，P<0.05）。結論 風濕免疫系統疾病患者應用羥氯喹聯合潑尼松治療的效果更加確切，能夠顯著改善患者關節腫脹與疼痛癥狀，且未明顯增加不良反應。

[關鍵詞] 風濕免疫系統疾病;羥氯喹;潑尼松;臨床療效

[中圖分類號] R593 ? ? ? ? ?[文獻標識碼] A ? ? ? ? ?[文章編號] 1674-0742（2020）07（b）-0098-03

[Abstract] Objective To explore the clinical efficacy of hydroxychloroquine combined with prednisone in the treatment of rheumatic immune system diseases. Methods 109 patients with rheumatic immune system disease who were treated in the hospital from May 2017 to May 2019 were convenient selected for group study and randomly divided into a control group （n=54） and a research group（n=55）. Patients in the control group were treated with prednisone， and patients in the study group were treated with hydroxychloroquine combined with prednisone. The clinical efficacy， incidence of adverse reactions， joint swelling index and pain index were compared between the two groups. Results The total clinical effective rate was 81.48% in the control group and 94.55% in the study group. The study group was significantly higher than the control group （χ2= 4.427， P<0.05）. The incidence of adverse reactions in the control group was 7.41%， and that in the study group was 9.09%. The data was not statistically significantly different （χ2=0.102， P>0.05）. Before treatment， the joint swelling index and pain index of the control group were （3.82±0.95） points and （3.50±0.84） points respectively， while those of the study group were （3.81±0.93） points and （3.52±0.81） points respectively，which difference was not statistically significant （t=0.120， 0.220， P>0.05）; after treatment， the joint swelling index and pain index of the control group were （1.77±0.51） points and （1.71±0.37） points respectively， and the study group patients were （0.68±0.42） points and （0.66±0.31） points， the study group was statistically significantly lower than the control group （t=6.540， 6.820， P<0.05）. Conclusion The effect of hydroxychloroquine combined with prednisone in patients with rheumatic immune system disease is more accurate. It can significantly improve the joint swelling and pain symptoms of patients， and does not significantly increase adverse reactions.